Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 26, 2026

Annual Results 2025: clear second half improvement, restructuring measures show first results

View original at globenewswire.com
Annual Results 2025: clear second half improvement, restructuring measures show first results Ad hoc announcement pursuant to Article 53 LR 26 February 2026 – 06:30 AM The Feintool Group’s business performance in the 2025 financial year reflects a market environment that remains challenging, with differing dynamics acr…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Around 60% of new orders relate to e-motor core projects in Europe and Asia

    80% confidence
  • Roughly one third of e-lamination stamping volumes are linked to automotive applications and around two thirds to industrial uses

    80% confidence
  • The global automotive market is growing at a low single-digit rate

    80% confidence
  • Global megatrends towards low-carbon energy generation, storage and mobility remain intact and continue to offer attractive growth potential

    80% confidence
  • The full annual earnings contribution from restructuring measures is expected to be realized from the 2026 financial year onwards, with associated annual savings of around CHF 12 million

    80% confidence
  • Restructuring measures have significantly reduced the break-even level

    80% confidence
  • Capital expenditure is expected to shift towards maintenance, efficiency-driven projects as well as selected capacity expansions, especially in North America and Asia, supporting a structurally improved free cash flow profile

    80% confidence
  • Feintool anticipates further improvement in EBIT margins in local currencies for 2026

    80% confidence
  • New sales-relevant, large-volume programs will start up across the group in 2026

    80% confidence
  • Feintool reaffirms its mid-term target of achieving an EBIT margin of more than 6%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com